Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 710
Filter
1.
Front Public Health ; 10:1048935, 2022.
Article in English | PubMed | ID: covidwho-2199525

ABSTRACT

OBJECTIVES: To investigate the prevalence of functional gastrointestinal disorders (FGIDs) related symptoms among healthcare workers (HWs) who were in the fighting against COVID-19 in Nanjing of China, and further to examine the association between working place and FGIDs-related symptoms among HWs during the period of COVID-19 epidemic. METHODS: An online anonymous survey was conducted among those HWs without history of FGIDs, who took part in the fighting against the COVID-19 epidemic between July and September of 2021 in Nanjing, China. All the 15 FGIDs-related symptoms included in the Rome IV diagnostic questionnaire for adults were investigated in this study. The outcome variable was the presence of FGIDs-related symptoms ("Yes" or "No"), while the independent measure was participants' working place ("in-ward" or "out-ward"). Logistics regression models were applied to calculate odds ratios (ORs) and 95% confidence intervals (CIs) to assess the association of working place with FGIDs-related symptoms among those healthcare workers. RESULTS: Totally, 336 eligible participants completed the survey. The prevalence of FGIDs-related symptoms was 48.8% (95%CI = 43.4%, 54.3%) among overall participants, with 40.7% (95%CI = 33.14%, 48.71%) and 56.3% (95%CI = 48.59%, 63.73%) for in-ward and out-ward HWs, respectively. Compared to their in-ward counterparts, those out-ward HWs were at a 1.88-fold likelihood (95%CI = 1.22, 2.89) to experience FGIDs-related symptoms during the period of fighting against the COVID-19 epidemic. After adjustment for potential confounders, such a positive association attenuated but still remained significant. CONCLUSIONS: A high prevalence of FGIDs-related symptoms was observed among those HWs who were without history of FGIDs during the fighting against COVID-19, and out-ward HWs were at a significantly higher risk to experience FGIDs-related symptoms relative to their in-ward counterparts in regional China. It has important implications that particular attention shall be paid to functional gastrointestinal issues for healthcare workers, especially those who are at uncertain risks of infectious diseases, when they participate in response to public health emergencies in future.

2.
Bmc Pregnancy and Childbirth ; 22(1), 2022.
Article in English | Web of Science | ID: covidwho-2196105

ABSTRACT

BackgroundThe positive predictive rate of the Japanese version of the Edinburgh Postnatal Depression Scale (EPDS) is lower than those of other versions. This study aimed to confirm whether the EPDS Japanese version reflects actual symptom frequency and to examine the possibility of improving the positive predictive rate. MethodsThis is a methodological study aimed at improving the positive predictive value of EPDS. The participants were 63 non-pregnant and 382 pregnant women. They answered the 10 questions of the Japanese version of the EPDS and reported the specific number of days as the frequency. The EPDS score (EPDS-S) and the frequency score (FREQ-S) were calculated for three factors of emotion: anhedonia, anxiety, and depression. ResultsThe positive rates of the EPDS-S and FREQ-S in pregnant women were 6% and 8%, respectively, which were lower than those in non-pregnant women (17%). On comparing the EPDS-S with the FREQ-S, a significant underestimation of frequency was observed in approximately 3% of pregnant women. The FREQ-S showed better internal consistency than the EPDS-S. Among the factors of emotion, women tended to rate anhedonia lower in the EPDS-S than in the frequency scale. ConclusionPregnant women tended to report a lower frequency on the Japanese version of the EPDS than their actual symptom frequency, which was especially true for those with a desire to self-harm. The combined use of the FREQ-S and EPDS-S can prevent underestimation and help improve the detection rate of depression.

3.
BMC geriatrics ; 23(1):1, 2023.
Article in English | EMBASE | ID: covidwho-2196062

ABSTRACT

BACKGROUND: Frailty is a physiological condition characterized by a decreased reserve to stressors. In patients with COVID-19, frailty is a risk factor for in-hospital mortality. The aim of this study was to assess the relationship between clinical presentation, analytical and radiological parameters at admission, and clinical outcomes according to frailty, as defined by the Clinical Frailty Scale (CFS), in old people hospitalized with COVID-19. MATERIALS AND METHODS: This retrospective cohort study included people aged 65 years and older and admitted with community-acquired COVID-19 from 3 March 2020 to 31 April 2021. Patients were categorized using the CFS. Primary outcomes were symptoms of COVID-19 prior to admission, mortality, readmission, admission in intensive care unit (ICU), and need for invasive mechanical ventilation. Analysis of clinical symptoms, clinical outcomes, and CFS was performed using multivariable logistic regression, and results were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). RESULT(S): Of the 785 included patients, 326 (41.5%, 95% CI 38.1%-45.0%) were defined as frail (CFS >= 5 points): 208 (26.5%, 95% CI 23.5%-29.7%) presented mild-moderate frailty (CFS 5-6 points) and 118 (15.0%, 95% CI 12.7%-17.7%), severe frailty (7-9 points). After adjusting for epidemiological variables (age, gender, residence in a nursing home, and Charlson comorbidity index), frail patients were significantly less likely to present dry cough (OR 0.58, 95% CI 0.40-0.83), myalgia-arthralgia (OR 0.46, 95% CI 0.29-0.75), and anosmia-dysgeusia (OR 0.46, 95% CI 0.23-0.94). Confusion was more common in severely frail patients (OR 3.14;95% CI 1.64-5.97). After adjusting for epidemiological variables, the risk of in-hospital mortality was higher in frail patients (OR 2.79, 95% CI 1.79-4.25), including both those with mild-moderate frailty (OR 1.98, 95% CI 1.23-3.19) and severe frailty (OR 5.44, 95% CI 3.14-9.42). Readmission was higher in frail patients (OR 2.11, 95% CI 1.07-4.16), but only in mild-moderate frailty (OR 2.35, 95% CI 1.17-4.75).. CONCLUSION(S): Frail patients presented atypical symptoms (less dry cough, myalgia-arthralgia, and anosmia-dysgeusia, and more confusion). Frailty was an independent predictor for death, regardless of severity, and mild-moderate frailty was associated with readmission. Copyright © 2022. The Author(s).

4.
Colorectal Disease ; 23(Supplement 2):51-52, 2021.
Article in English | EMBASE | ID: covidwho-2192481

ABSTRACT

Aim: Gastrointestinal (GI) symptoms have been reported with coronavirus disease (COVID-19), but our understanding of their clinical significance is limited and this can be a safety concern for surgeons as patients might present with GI symptoms only. Method(s): A prospectively maintained database of emergency patients was reviewed between 20/03/2020 and 20/04/2020 (Cohort A) and 05/01/2021-26/ 01/2021. (Cohort B) All of them had a positive Polymerase Chain Reaction (PCR) COVID-19 test. We evaluated the prevalence of GI symptoms and their association with the severity of COVID-19 and looked at the prevalence of symptoms in different ethnicities. Chi-squared test in R software environment was used to analyse the data. Result(s): Cohort A consisted of 189 patients (100 male) 14 had nausea, 18 vomiting, 39 diarrhoea and 9 abdominal pain. 17 had ITU admissions and 68 died. Cohort B consisted of 348 patients (185 male) 50 had nausea, 46 vomiting, diarrhoea 84 and 23 had abdominal pain. 30 had ITU admissions and 75 died. In this cohort the COVID-19 Alpha Variant was making up nearly 100% of cases. Nausea was more common in Cohort B 50/348 (P = 0.01641) There was no difference in vomiting (18/189 Cohort A P = 0.198898), diarrhoea (39/189 Cohort A, P = 0.3385) and abdominal pain (9/189 Cohort A P = 0.379). There was no difference in GI symptoms for the severe and non-severe cases in Cohort A (P = 0.150813) but they were more prevalent in the non-severe group of Cohort B (P = 0.008). There was no diifference between ethnic groups in terms of GI symptoms (Cohort A 35 Black patients,17 Asian, 102 White and 35 Other Ethnicities, Cohort B 40 Black, 33 Asian, 174 White and 101 Other Ethnicities). Conclusion(s): Acute GI symptoms associated with COVID-19 are highly prevalent and were seen more often in non-severe cases of Cohort B. The SARS-CoV- 2 Alpha Variant was endemic in our region and the UK vaccination programme was being rolled out at the time of our study. More research is required to establish the significance of these factors.

5.
5th International Conference on Informatics and Computational Sciences, ICICos 2021 ; 2021-November:139-143, 2021.
Article in English | Scopus | ID: covidwho-2191859

ABSTRACT

This research aims to determine the symptoms of being infected with Covid-19 using a fuzzy logic approach. Detection of Covid-19 is an important step in early identification of suspected Covid-19 patients so that further steps can be taken. Fuzzy logic is an appropriate way to map an input space into an output space. For very complex systems, the use of fuzzy logic is one solution. Research results can help the community to carry out self-diagnosis, and paramedics to carry out initial diagnoses to patients, so that it can make it easier for all parties to deal with Covid-19. From the test result with 176 individuals obtained an accuracy value of 93.7%. © 2021 IEEE.

6.
Pediatric Critical Care Medicine Conference: 11th Congress of the World Federation of Pediatric Intensive and Critical Care Societies, WFPICCS ; 23(11 Supplement 1), 2022.
Article in English | EMBASE | ID: covidwho-2190804

ABSTRACT

BACKGROUND AND AIM: The clinical spectrum and management of Multi-system Inflammatory Syndrome in Children (MIS-C) is evolving with each wave of COVID-19. This study aims to compare the clinical spectrum and immunomodulatory management of children with MIS-C between first and second wave in a tertiary care hospital in south India. METHOD(S): This prospective observational comparative study included children satisfying CDC MIS-C criteria admitted during 1st and 2nd wave of COVID 19 (total period from September 2019 to January 2022). We compared the clinical presentation, severity of illness, inflammatory biomarker profile, immunomodulatory therapy, need for inotropic support, duration of stay and outcome. RESULT(S): Study population included 27 during 1st wave and 75 during 2nd wave. Median age (IQR) of patients was 4.4years (3.15, 7.95) and 5.6 years (3.25, 8.8) during 1st and 2nd wave respectively. Males preponderance was seen in both waves (69% VS 65%). Clinical presentation was similar in both waves. 37% patients presented with shock during 1st wave while 36% in 2nd wave. Gastrointestinal symptoms were predominant (78% VS 82%) followed by cardiac manifestations (44% VS 45%), while a higher incidence of coronary artery dilatation was seen in 2nd wave (35% VS 26%). Comparison of immunomodulatory therapy is depicted in table 1. IVIG and pulse Methylprednisolone requirement was more during 2nd wave. 3 patients during 2nd wave needed additional immunomodulatory therapy with Anakinra (table 1). No patient required 2nd dose of IVIG. There was no mortality. CONCLUSION(S): Clinical presentation was similar in both waves. Requirement of immunomodulatory therapy was more during 2nd wave.

7.
Pediatric Critical Care Medicine Conference: 11th Congress of the World Federation of Pediatric Intensive and Critical Care Societies, WFPICCS ; 23(11 Supplement 1), 2022.
Article in English | EMBASE | ID: covidwho-2190744

ABSTRACT

BACKGROUND AND AIM: Pediatric inflammatory multisystem syndrome temporally associated with COVID- 19(PIMS-TS)is a new spectrum of COVID-19's related clinical manifestations associated to increased inflammatory markers. We aim to describe clinical and biological characteristics of PIMS-TS patients admitted to PICU. METHOD(S): Were included children (1month -14years old) admitted to our PICU from March to October2021 for PIMSTS according to WHO's definition. RESULT(S): Ten patients (6 girls/4 boys) were included. Mean age was 8 years(1.8-13 years). Clinical manifestations: Fever (all cases, mean duration:5 days);gastrointestinal symptoms (3 cases);mucocutaneous signs (8 cases), neurological impairment(3 cases). Shock was diagnosed in 6 cases and hypoxemia in 4 cases. RT-PCR of SARS-COV2 was negative while Serology returned positive in all cases. Biology assessment: Mean white blood cells account was 21154 E/mm3 (14783- 48190 E/mm3);mean lymphocytes account was 1047,2 (651-1610 E/mm3);mean C-reactive protein was 247,2 mg/l (147-401mg/l);hyperferritinemia >500 ng/ml was noted in 8 cases with a mean level of 712,4 ng/ml (543-1004 ng/ml);D-Dimeres level>1000mug/ml in all cases with a mean level of 2076,2 ng/ml (1100-3292 ng/ml);Troponin were positive in 7 patients with a mean level of 53,7 (12-120ng/l). Transthoracic echocardiogram was normal in 4 cases, ventricular dysfunction was objectified in 6 cases. Mechanical ventilation was necessary in three cases. Vasoactive support was administrated in 7 cases. Bolus of methylprednisolone associated to intravenous immunoglobulins were administrated in 8 cases. The average length of PICU stay was 6 days (2-10 days). The outcome was favorable in 7 cases. CONCLUSION(S): PIMS-TS has multiple faces and can be lethal in children.

8.
Open Forum Infectious Diseases ; 9(Supplement 2):S895-S896, 2022.
Article in English | EMBASE | ID: covidwho-2190026

ABSTRACT

Background. Families with children may be at higher risk for influenza infection. Community transmission can suffer from underreporting as testing is often not performed. We studied the epidemiology of influenza in households with school-aged children using home-based sample collection. Methods. We conducted a remote household study surveilling respiratory viruses from November 2019-June 2021, in King County, Washington (WA), USA. Households with school-aged children were enrolled, mailed home specimen collection kits, and asked to self-assess for weekly acute respiratory illness (ARI) using remote survey platforms. Participants with ARI symptoms were prompted to complete serial illness surveys and self-collect/parent collect mid-turbinate nasal swabs. Samples were sent to a University of Washington study laboratory for RT-PCR influenza testing. Influenza rates were compared to WA Department of Health (DOH) reporting. Results. A total of 1861 ARI events were reported among 992 adults and 869 children in 470 households;75 influenza cases were detected (36 influenza A and 39 influenza B). The study participant median age was 32 years (0-84), 10 years (1-49) for influenza A, and 11 years (3-49) for influenza B cases. Overall 13% of households had an influenza case, of which 13 (22%) reported >1 case. A total of 81% of participants reported receipt of one dose of the 2019-2020 influenza vaccine, including 91% of influenza A and 90% of influenza B cases, and 84% received the 2020-2021 influenza vaccine. Like WA DOH, we observed a wave of influenza B cases followed by influenza A in 2019-2020. During influenza season 2020-2021, WA DOH reported 9 positive influenza tests and none observed in our study. Commonly, influenza case-patients reported were fever, cough, rhinorrhea, and fatigue. GI symptoms were more common in children than adults. Of the cases, 92% of influenza A and 78% of influenza B occurred in children. Conclusion. Influenza illness in 2019-2020 was initially influenza B, and subsequently replaced by influenza A. Most cases were in children and adolescents, despite at least one dose of influenza vaccine. Symptoms were widely distributed and similar between influenza A and B. Influenza incidence in our cohort declined to zero with the rise of SARS-CoV-2 cases and widespread mitigation efforts. (Figure Presented).

9.
Open Forum Infectious Diseases ; 9(Supplement 2):S197, 2022.
Article in English | EMBASE | ID: covidwho-2189612

ABSTRACT

Background. MIS-A frequently presents with symptoms including fevers, cardiovascular, gastrointestinal mucocutaneous, and neurologic involvement in both children and adults. Predominantly occurs in previously healthy children and young adults, disproportionately affecting individuals of African, Latino and Asian descent. Represents one of the most significant and yet under-recognized clinical consequences of SARS-CoV-2 infection. Methods. A retrospective review was performed of the identified MIS-A cases admitted to two institutions between January 2020-December 2021. Included cases required evidence of present or previous SARS-CoV-2 infection by either PCR or antigen testing;and meeting the CDC definition for MIS-A. After case identification, we collected clinical and laboratory data to analyze demographics, clinical symptoms, laboratory result, imaging, length of hospitalization and therapeutic interventions. Results. Ten cases were identified in the established period of time. The average interval to hospital admission was 31days. Clinical symptoms included fever, malaise, gastrointestinal complaints, dyspnea, diffuse rash. Males outnumbered females in a ratio of 7:3, with African American and Latino patients comprising 80% of the cases. All patients had elevated inflammatory markers and the most commonly manifesting organ dysfunction was cardiovascular system. Conclusion. This case series helps reinforce the characterization of an as yet incompletely understood and challenging clinical syndrome, providing insight to guide diagnosis and treatment of MIS-A. A greater understanding of MIS-A may facilitate earlier syndromic recognition in order to improve outcomes, reduce unnecessary antimicrobial use, and reduce costs.

10.
Ann Work Expo Health ; 2022.
Article in English | Web of Science | ID: covidwho-2188245

ABSTRACT

OBJECTIVES: We estimated influenza-like symptom (ILS) incidence among healthcare personnel (HCP) in four hospitals and the economic impact due to ILS in the Thai HCP population during July 2020-June 2021 (Thailand's expected 2020 influenza season), which also coincided with the novel coronavirus disease 2019 pandemic. METHODS: We followed HCP, in a prospective observational cohort, weekly for >/=1 of: muscle pain, cough, runny nose/nasal congestion, sore throat, or difficulty breathing. We fitted population-averaged Poisson regression models to identify factors associated with acquiring ILS and to calculate ILS incidence. We applied epidemiologic parameters to Thailand's HCP population (227 349 persons) to estimate economic impact. RESULTS: Of 2184 participants, adjusted all-cause ILS incidence was 6.1 episodes per 100 person-years (95% confidence interval 3.4-10.9). Among Thailand's HCP population, 13 909 ILS episodes were estimated to occur annually and would result in US$235 135 economic loss. Controlling for study site and calendar month, factors associated with acquiring >/=1 ILS versus no ILS included being female, having asthma, and using personal protective equipment 'frequently, but not always'. CONCLUSIONS: All-cause ILS resulted in considerable economic loss among Thai HCP workforce. These findings underscore the importance of public health interventions to reduce the risk of acquiring ILS.

11.
The Lancet Respiratory Medicine ; 11(1):e4, 2023.
Article in English | EMBASE | ID: covidwho-2184788
12.
Journal of Infection and Public Health ; 2023.
Article in English | ScienceDirect | ID: covidwho-2180686

ABSTRACT

Objective: The spread of the novel SARS-Cov-2 variant Omicron created a challenging public health situation in a number of countries. In March 2022, Omicron emerged in Changchun, China, and the number of patients infected rapidly increased. The prevalence of Omicron infection symptoms differs from that of Delta, with more upper airway clinical symptoms apparent. This study aimed to investigate the clinical and upper airway characteristics of the Omicron variant. Materials and methods In this retrospective study, we collected data from participants in Changchun who had tested positive for Omicron with quantitative polymerase chain reaction between 10 March and 30 May 2022 using telephone interviews. The questionnaire was designed by the research team based on the number of upper airway symptoms using the visual analogue scale. We also considered age, sex, vaccination status, general symptoms, and cure period. Results A total of 3715 patients (2056 males and 1659 females) with mild COVID-19 from the Omicron variant were included. The patients had a mean age of 38.63 (±13.97) years (range 2 to 86 years). The vaccine uptake rate was 91.33% (8.66%, 4.58%, 65.33%, and 21.43% had received zero, one, two, and three doses, respectively). The incidence of upper airway symptoms, including throat and nasal symptoms, was 54.21%. Throat symptoms were the most common during Omicron infection (49.12%). Nasal symptoms were also common (20.08%). The incidence of lower airway symptoms was 25.60%, and gastrointestinal symptoms was 10.87%. The incidence of general symptoms was 55.26%. The cure period ranged from three to 37 days, with a mean of 10.24±4.69 days. We compared the upper airway symptom severity for Omicron among different vaccination statuses and found no differences. Conclusions: The main clinical characteristics of the SARS-Cov-2 Omicron variant are upper airway symptoms and general symptoms. Fever remains the most common symptom, followed by mild dry cough. There was no association between Omicron infection and COVID-19 vaccines, and the vaccination status might have been ineffective against upper airway symptom severity by Omicron.

13.
Heliyon ; : e13090, 2023.
Article in English | ScienceDirect | ID: covidwho-2179059

ABSTRACT

Objective During the coronavirus disease 2019 (COVID-19) pandemic, an increased mental burden has been widely reported among medical health workers such as physicians and nurses. However, data on laboratory technicians exposed to COVID-19 have rarely been published. The aim of this study was to assess the magnitude of psychological symptoms among laboratory technicians and analyze potential risk factors associated with these symptoms. Methods A cross-sectional online survey was performed via the Wenjuanxing platform (a professional online questionnaire platform) (https://www.wjx.cn/mobile/statnew.aspx) to investigate the mental health of laboratory technicians during the COVID-19 pandemic in Hebei, China from October 4, 2021, to November 3, 2021. The online questionnaire included demographic and occupational characteristics data of responders, and the Symptom Check List-90-Revised (SCL90-R)was used to quantify the magnitude of psychological symptoms among laboratory technicians. Participants' demographic and occupational characteristics were analyzed using descriptive statistical analyses. Chi-square tests were applied to compare the severity of each symptom between two or more groups. A binary logistic regression model was developed to identify the predictors of laboratory technicians' mental health in response to the COVID-19 pandemic, and outcomes are presented as odds ratios and 95% confidence interval. Statistical analysis was performed using SPSS version 21 (SPSS, New Orchard Road, Armonk, New York, USA). Results A total of 3081 valid questionnaires were collected. Of these 3081 participants, 338 (11.0%) reported a total SCL90-R score >160, which indicated positive psychological symptoms. Among the 338 participants who reported psychological problems, most of them were mild symptoms. Several factors associated with mental health problems in laboratory technicians during COVID-19 were found, which include a history of physical and/or psychological problems (all 10 symptoms p < 0.001), more than 10 years of work experience (depression symptoms: OR = 2.350, p = 0.024;anxiety symptoms: OR = 2.642, p = 0.038), frontline work (depression symptoms: OR = 1.761, p = 0.001;anxiety symptoms: OR = 2.619, p < 0.001;hostility symptoms: OR = 1.913, p = 0.001), participant in more than 3 times large-scale SARS-CoV-2 screenings and more than 36 h per week in SARS-CoV-2 nucleic acid testing. Conclusion A portion of laboratory technicians reported experiencing varying levels of psychological burden. During the COVID-19 pandemic, multiple interventions should be developed and implemented to address existing psychosocial challenges and promote the mental health of laboratory technicians.

14.
Neurological Sciences ; 43(Supplement 1):S299-S300, 2022.
Article in English | EMBASE | ID: covidwho-2174291

ABSTRACT

Objectives: To determine the prevalence and characteristics of post-COVID- 19 (PC) in a group of patients with migraine, and the possible influence on PC of following a Ketogenic Diet (KD) as migraine prophylaxis. Materials: It is a retrospective, multicentric, observational study on a group a patient with migraine who had previously contracted COVID-19, Inclusion criteria were diagnosis of migraine according to the International Classification of Headache Disorders 3rd version, be between the ages of 18 and 65 years old, having been infected by SARS-CoV-2 as confirmed by specific tests (polymerase chain reaction or antigenic) positivity, acceptance to participate to the study. Diagnosis of PC was given in presence of persistence or increase of any COVID-19 symptoms after recovery by the acute phase of disease [1]. All the PC symptoms were collected. By clinical records, patients were segregated in 2 groups: who was following the diet during and after SARS-CoV2 infection, or not. Result(s): On 364 consecutive patients with migraine, seventy-eight meet inclusion criteria. Of them, fifty-one resulted to be positive to PC (ranging from 1 to 8 simultaneous symptoms), twenty-seven not;twentyseven patients were undergoing treatment by KD during and after viral infection. We collected 12 different groups of PC symptoms among our patients: Fatigue (72.54%);Dyspnea and other pulmonary symptoms (66.67%);Cognitive impairment and concentration difficulties (50.98%);Fibromyalgia, muscle pain and arthralgia (45.1%);Headache worsening/ Changes (43.14%);Thoracic pain (35.29%);Cough and other ear-noseand- throat (ENT) symptoms (33.33%);Sleep disorders (21.57%);Postural orthostatic tachycardia syndrome (POTS), paroxysmal tachycardia, and other cardiac symptoms (15.69%);Dizziness (9.8%);Heartburn, diarrhea and other gastrointestinal symptoms (7.84%);Persistent fever (3.92%). Out of 51 patients with PC, 8 were following KD, 43 not (Yates's chi-squared test= 20.97;p<0.001;OR= 0.078;C.I.= 0.026- 0.240). The mean number of symptoms was 1.50+/-0.76 for KD group, 4.53+/-1.47 for the others (t= 8.7;p<0.001). Discussion(s): PC is very prevalent among migraine patients and KD seems to be protective against it, as already suggested for its anti-inflammatory activity and its capacity to taper acute COVID-19 symptoms [2], although it is also possible that a role is also played by nutraceuticals that are supplemented during KD. Conclusion(s): PC is an emerging health issue also among subjects with migraine, and KD should be further studied to understand its promising role in the prevention of this syndrome.

15.
Neurological Sciences ; 43(Supplement 1):S336, 2022.
Article in English | EMBASE | ID: covidwho-2174268

ABSTRACT

Background: SARS-CoV-2 vaccination has been associated with rare neurological syndromes. The aim of this study is to evaluate the risk of association between specific neurological symptoms and syndromes and SARS-CoV-2 vaccination. Method(s): In this prospective single center cohort study, we included all adult inpatients consecutively admitted to a tertiary Neurological Centre from January 2021 to February 2022. Vaccinated cases were subgrouped according to the onset of neurological manifestation in the first 30 days (V<30d), 30-60 days (V30-60d) and more than 60 days (V>60d) following SARS-CoV-2 vaccination. The incidence and characteristics of neurological syndromes were compared between unvaccinated and vaccinated cases (including subgroups) adjusting for the effect of age, sex and premorbid conditions in linear regression analyses. Result(s): 830 subjects entered the study, namely 398 unvaccinated (UVC) and 432 vaccinated cases;these groups were comparable for demographic characteristics and clinical diagnosis distribution and. Compared to UVC, V<30d exhibited higher prevalence of Medical unexplained symptoms (MUS, 24.5% vs 10.6%), primary headache (10.9% vs 5%) and lower number of cerebrovascular diseases (30.7% vs 41.9%). V30-60d cases exhibited higher number of primary headache (13% vs 5%) compared to UVC, whereas V>60d showed similar diagnosis distribution with UVC. Conclusion(s): Unexplained transient neurological symptoms and primary headache appeared to be the most common neurological conditions following SARS-CoV-2 vaccination. The findings confirmed the safety of SARS-CoV-2 vaccination and argued against a prominent role in the pathogenesis of either cerebrovascular or inflammatory-mediated neurological disorders, exception made for rare CVT cases.

16.
Neurological Sciences ; 43(Supplement 1):S448-S449, 2022.
Article in English | EMBASE | ID: covidwho-2174260

ABSTRACT

Background and aims: COVID-19 pandemic caused a significant disruption of clinical activities at Multiple Sclerosis (MS) Centers. As part of a national multicenter survey (COVId Ms Patients SATisfaction survey - COVIMPSAT) aimed at collecting patients' opinion regarding the quality of care and information received fromMS Centers (MSC) during the first pandemic waves, we report data about COVID-19 infections and vaccination cycle and how they were managed by the MSC. Material(s) and Method(s): In April-May 2021, 16 Italian MSC developed and sent a digital (35-item) survey by email to their patients. Statistical analyses were performed with SPSS, version 25. Result(s): 1670 people with MS (pwMS;67.3% women) completed the survey. 169 (10.1%) reported a diagnosis of COVID-19 infection: 63% were symptomatic, while 37% were not. As regards treatment for COVID-19, only 3% of the patients were hospitalized. The impact of COVID-19 infection on MS-related neurological symptoms was as follow: 69.3% of pwMS stated that the severity of their MS-related symptoms remained stable, 21.5% reported a worsening of pre-existing symptoms, 7.4% affirmed that new neurological symptoms emerged, while only 1.8% reported an improvement of MS-related symptomatology. At the time of the survey, 60.6% of pwMS were inoculated at least one dose of COVID-19 vaccine. Vaccination appointments were scheduled by: MSC staff alone (44.9%), MSC staff together with the general practitioner (17.5%), the general practitioner alone (16.1%), other Institutions (12.1%), and by the patients themselves (9.3%). At the moment of the survey 39.4% of pwMS were not vaccinated yet. The three major reasons for not being vaccinated yet were: being already on a vaccination list (40.8%), willing to be vaccinated but without an appointment (17.6%), still undecided or not willing to be vaccinated (19.3%). Discussion(s): The results of this multicentrer survey revealed a low hospitalization rate of pwMS, in line with previous studies [1]. In the majority of the sample, COVID-19 symptomatology did not have a significant impact on MS-related neurological symptoms. MSC promoted and facilitated vaccination procedures and scheduling, alone or in combination with the general practitioner, in more than half of pwMS.

17.
Medicina ; 82(6):971-973, 2022.
Article in Spanish | MEDLINE | ID: covidwho-2169196

ABSTRACT

During the past two years we have witness a tremendous worldwide health crisis imposed by the coronavirus disease (COVID-19). This situation led to the urgent development and implementation of vaccines in an attempt to decrease not only the SARS-CoV-2 transmissibility but also the severe forms of COVID-19. Although these vaccines were approved based on an adequate benefit-risk ratio, at the moment of their implementation in 2021 we did not have sub-studies in special populations;patients with systemic lupus erythematosus (SLE) among them. We describe two cases of lupus nephritis flare following the immunization against SARS-CoV-2 with the first component of Sputnik V and Sinopharm. Both patients were in complete remission on maintenance therapy with mycophenolate and without glucocorticoids. The flare presented with an increased protein/creatinine ratio in urine and positive anti-DNA antibodies without other relevant accompanying findings. After treatment with prednisone (20 y 10 mg/day in case 1 and 2, respectively) and an increased dose of mycophenolate (from 1.5 g/day to 2.0 g/dayand 1.08 to 1.44 g/dia of sodic mycophenolate in case 1 y 2, respectively) both patients regained renal remission. These cases are of relevance as they introduce a possible association between the different anti-SARS-CoV-2 vaccine platforms and SLE flares;at the same time to suggest the need for close control in the post vaccination period in this population of patients.

18.
Palliative Care in Lung Disease ; : 345-372, 2021.
Article in English | Web of Science | ID: covidwho-2168210
19.
US ; Pharmacist. 47(12):1, 2022.
Article in English | EMBASE | ID: covidwho-2167900
20.
Research Journal of Pharmacy and Technology ; 15(11):5202-5205, 2022.
Article in English | EMBASE | ID: covidwho-2207044

ABSTRACT

Background: WHO has declared Coronavirus 2019 (COVID-19) as pandemic on 11th March 2020. Hydroxychloroquine (HCQ) chemoprophylaxis has been approved by the Indian Council of Medical Research (ICMR) for asymptomatic healthcare workers treating suspected or confirmed COVID-19 cases and asymptomatic household contacts of confirmed patients. However, there is a scarcity of data regarding the efficacy and safety of HCQ for COVID-19 prophylaxis and treatment. Objective(s): The present study was designed to evaluate the adverse drug reaction (ADR) profile of HCQ prophylaxis among healthcare workers in a tertiary care teaching hospital in India. Method(s): A Descriptive cross-sectional study was conducted in Kalpana Chawla Medical College and Hospital, Karnal for duration of 3 months (April-June 2020). The study was performed on the reported ADRs due to HCQ prophylaxis by the healthcare workers to the ADR monitoring centre of the institute during this period. Result(s): Gastrointestinal disturbance such as loose stool (16.4%) and hyperacidity (14.9%) were the most commonly reported ADRs during the study period. The incident rate of adverse drug reactions was 23.7%. The number of ADRs was found to be significantly (p<0.01) more in female as compared to male. We have observed that most of the reactions were reported following the 1st day loading dose. Conclusion(s): Our results showed that gastrointestinal system was most commonly affected. Loose stool and hyperacidity were most frequently reported ADRs due to HCQ prophylaxis. Larger studies are required to ensure the safety of the use of HCQ as prophylaxis for COVID-19. Copyright © RJPT All right reserved.

SELECTION OF CITATIONS
SEARCH DETAIL